A place for peculiar ideas.

Research article / 5 minute read

US 5,336,499: Antelman's Granted 'Molecular Crystal Device for Pharmaceuticals' Patent, Its Broth Figures and Its Paper Trail

US 5,336,499 is the United States patent in which Marvin S. Antelman applies his Molecular Crystal Device (Electron Jumping Compound) concept to pharmaceuticals, as its title says. Elsewhere in this dossier it appears only as a line in Antelman's patent lists, paired with its continuation US 5,571,520. The Google Patents record gives the text behind that line: what the patent says the crystal is, how it is supposed to kill microbes, which laboratory figures it reports, and what happened to the patent afterwards.

The filing in brief

According to the record, the application (US 07/971,933) was filed on 5 November 1992 by Antelman Technologies Ltd, with a priority date of 10 January 1992. It is listed as a division of an application filed that same January day. The patent was granted and published on 9 August 1994. A continuation filed on 4 August 1994, titled Molecular crystal redox device for pharmaceuticals, became US 5,571,520 (published 5 November 1996). The classifications place the patent among topical skin preparations, silver-containing medicinal preparations, biocides, cosmetic preservatives and antimicrobial barrier preparations. They also include the class for injectable compositions.

What the patent says the crystal is

The patent describes tetrasilver tetroxide, Ag₄O₄, as a diamagnetic semiconducting crystal. In the patent's account, each molecule combines four oxygen atoms with four silver ions, two of them monovalent and two trivalent (see Tetrasilver Tetroxide (Ag₄O₄)). The patent gives 2.1 Å as the spacing between the Ag(III)–O and Ag(I)–O units, and states that each trivalent ion is bonded to four oxygens through dsp² bonds. Antelman notes that the Merck Index (11th edition, entry 8469) calls the oxide silver(II) oxide, AgO, and asserts that at the molecular level it is actually Ag₄O₄. For his depiction of the lattice he cites crystallographic work by J. A. McMillan and neutron-diffraction studies by Alvin J. Salkind and coworkers.

He presents the invention as a follow-on to his divalent-silver bactericide patents. The text names US 5,017,285, plus 5,078,902, 5,073,382, 5,089,275 and 5,098,582. The record's own citation list gives the first of these as US 5,017,295, Divalent silver bactericide for water treatment. That suggests a typographical slip in the description.

How it is claimed to work

The patent's stated aim is a single-crystal device that kills viruses, bacteria, fungi and algae "when operating in conjunction with other such devices". It proposes using the crystals in pharmaceuticals, as a preservative in cosmetic and chemical-specialty products, and in cooling towers, swimming pools, hot tubs and municipal water supplies.

The mechanism the patent proposes is the one drawn in Antelman's Microorganism-and-Lattice Schematic: Power Flux, the Activation Control and the Ag₄O₄ Structure. Silver's affinity for sulfur and nitrogen in the cell membrane is said to draw the crystal onto the microbe. According to the patent, electrons then pass from the monovalent to the trivalent silver ions through the surrounding water, crossing the membrane on the way. Electrons from neighbouring crystals add to the effect, and the patent puts "electrocuted" in quotation marks for the result. Two half-reactions summarise the step: Ag⁺ loses an electron, Ag³⁺ gains one, and the crystal ends with every silver ion divalent. Using a 1.98 V (about 2.0 V) Ag(I)→Ag(II) potential taken from Antelman's own Encyclopedia of Chemical Electrode Potentials (Plenum 1982, page 88), the patent multiplies voltage by the electron charge to get 3.2 × 10⁻¹⁹ watts. The dossier's critique of that arithmetic is on Molecular Crystal Device (Electron Jumping Compound).

The crystals are said to do nothing unless an oxidising agent activates them. Antelman likens this to etching the surface of a copper indium selenide photovoltaic. The activators were persulfates, ranging from Du Pont's Oxone (potassium monopersulfate) to alkali peroxydisulfates. The patent reports that the persulfates alone showed no antipathogenic activity at the chosen optimum of 10 PPM (see Persulfate Activation).

What was actually measured

The laboratory material consists of in-vitro broth tests. The bacteria were grown in trypticase soy broth (BBL 11766), with inocula prepared to AOAC specifications at 0.6–1 million organisms per 0.05 ml drop. The patent tested three staphylococcal strains, Staphylococcus aureus 9027 and 27543 and S. epidermidis 12228, because of their association with hospital infection. The patent says that once a microbe proved susceptible, the minimal concentration that inhibited it in broth was determined.

Table I gives one number per organism, labelled "Power Flux". The patent gives no unit for it. Other pages in this dossier describe power flux as an arbitrary metric proposed by Antelman (see Molecular Crystal Device (Electron Jumping Compound) and Antelman's Microorganism-and-Lattice Schematic: Power Flux, the Activation Control and the Ag₄O₄ Structure). Grouped from lowest to highest value, the eight entries are:

Power Flux value Organisms listed at that value
12.5 S. epidermidis
25.0 M. luteus, P. aeruginosa
50.0 C. albicans, E. coli, S. aureus, Strep. faecalis, Strep. pyogenes

For yeasts, algae and moulds the patent switched to Sabouraud dextrose broth. It reports total killing of the yeast Candida albicans at 2.5 PPM, and of a strain it labels the "Saccharomycetpideae variety" at 1.25 PPM.

What the document does and does not establish

These are the inventor's own test-tube figures in a patent filing. The patent reports one control, persulfate tested on its own. The Table I figures carry no stated unit, uncertainty or replicate information, and the table does not state how its "Power Flux" values relate to the minimal inhibiting concentrations the patent says were determined. The text does not show that electrons reach a microbe, or that the killing differs from ordinary oxidant or silver-ion action. Inhibition in nutrient broth says nothing about safety or effect in a living body, and a granted patent is not evidence that a product works.

The patent's later life

The legal record shows fee payments at four years (1998) and eight years (2002). The patent then lapsed on 9 August 2006 because the next maintenance fee went unpaid. Ownership moved several times. It was assigned to Marantech Holding LLC in 2001 (two recorded assignments) and back to Antelman Technologies in May 2002. A 2008 assignment to Aidance Skincare & Topical Solutions LLC lists Marantech as assignor, although the earlier entries show Marantech had already handed the patent back.

The patent is cited by many later filings. They include Antelman's US 5,676,977 (published 1997), whose title claims a method of curing AIDS with the same crystal devices; Marantech patents on skin conditions, textiles and cancer; and Aidance's "Silver oxide formulations" family, most recently US 12,485,142 B2 (2 December 2025). That line of citations runs from this broth-test patent to the AIDS claims examined in WO 2003/043537: Antelman's 2001 'Improvements' Patent Application, the South African Tetrasil Cases and the Hepatomegaly Admission and Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Bounded Evidence.

Source notes & attribution
  1. https://patents.google.com/patent/US5336499A/en